The farnesyltransferase inhibitor tipifarnib protects against autoimmune hepatitis induced by Concanavalin A
- 3 April 2020
- journal article
- research article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 83, 106462
- https://doi.org/10.1016/j.intimp.2020.106462
Abstract
No abstract availableKeywords
Funding Information
- JSPS (16K10963, 19k09374)
This publication has 42 references indexed in Scilit:
- Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cellsHaematologica, 2012
- Immune mechanisms of Concanavalin A model of autoimmune hepatitisWorld Journal of Gastroenterology, 2012
- Farnesyltransferase Inhibitor FTI-277 Reduces Mortality of Septic Mice along with Improved Bacterial ClearanceJournal of Pharmacology and Experimental Therapeutics, 2011
- Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnibExpert Opinion on Investigational Drugs, 2010
- Delayed rejection of MHC class II-disparate skin allografts in mice treated with farnesyltransferase inhibitorsTransplant Immunology, 2009
- Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activityBlood, 2007
- Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional levelBlood, 2007
- Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cellsLeukemia, 2002
- Targeted Genomic Disruption of H-ras and N-ras, Individually or in Combination, Reveals the Dispensability of Both Loci for Mouse Growth and DevelopmentMolecular and Cellular Biology, 2001
- Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin AGastroenterology, 1996